



Supplemental Figure 7: Mean growth curves of subcutaneous 4T1 (n= 10 per group) tumors treated with isotype control antibodies, anti-mCCR8-IgG2a, anti-PD-1, or the combination of anti-mCCR8-IgG2a and anti-PD-1 antibodies at 0.2 mg/mouse/treatment at day 7, 10 and 14 after tumor implantation.